Once a niche medication for managing type 2 diabetes, Ozempic has rapidly become a cultural phenomenon—celebrated for dramatic weight loss, criticized for contributing to drug shortages, and now attracting attention for a far more audacious possibility: could it help prevent Alzheimer’s disease? As media buzz collides with pharmaceutical marketing and genuine scientific curiosity, it’s worth asking: how much of this excitement is backed by evidence?
At the heart of the conversation are glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs that has fundamentally changed the treatment landscape for both diabetes and obesity. Semaglutide—sold as Ozempic—is among the most potent and promising. While its effectiveness in improving blood sugar control and reducing cardiovascular risk is well established, new research hints at broader effects, including potential neuroprotective benefits. This article examines the science, speculation, and reality behind one of the most widely discussed drugs in modern medicine.
(Note: About Us, a reference bibliography, related books and videos are all found at the end of this article.)
